Neglected Tropical Diseases Diagnosis Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The NTD diagnosis market covers diagnostic products used to identify a portfolio of twenty neglected tropical diseases disproportionately affecting low- and middle-income countries in tropical and subtropical zones. The market was valued at approximately $6.8 billion in 2024 and has continued climbing through 2025-2026, with 2026 figures placing it near $7.64 billion and projections pointing toward roughly $9.6 billion by 2030 at a CAGR of approximately 6.0-6.1 percent. By comparison, the broader NTD treatment market stands at a smaller scale of approximately $3.7-3.9 billion, confirming that diagnosis represents the dominant segment within the overall NTD therapeutics and diagnostics ecosystem.

• •2024 market size: ~$6.78-6.8B; 2026 size: ~$7.5-7.8B; 2030 projection: ~$9.59-9.6B
• •CAGR: approximately 6.0-6.1 percent across major forecast periods
• •Diagnosis segment is materially larger than the treatment segment (~$3.7-3.9B in 2024-2025)
• •Long-range projections extend to $13.0-15.1B by 2035

Sustained growth in the NTD diagnosis market is anchored by the World Health Organization's 2021-2030 NTD road map, which calls for intensified surveillance, expanded access to diagnostics, and integration of NTD services into primary healthcare systems. International funding commitments from bodies such as the Gates Foundation, USAID, and the UK Foreign Office, combined with national program budgets in endemic countries, create stable demand. Concurrently, advances in lateral flow assays, loop-mediated isothermal amplification (LAMP), and other low-cost molecular platforms are making diagnostics viable in remote, resource-constrained settings previously unreachable by conventional laboratory infrastructure.

• •WHO NTD road map (2021-2030) targeting control, elimination, and eradication of twenty diseases fuels public-sector procurement
• •Sustained multilateral and philanthropic funding streams create predictable long-term demand
• •Technological progress in rapid tests and point-of-care molecular platforms expands addressable geography
• •Integration of NTD programs into broader primary care and infectious disease frameworks broadens distribution channels

Diagnostic technology segments typically include rapid diagnostic tests (lateral flow assays), immunoassays and ELISA-based systems, molecular diagnostics (PCR and isothermal amplification), and microscopy or culture-based methods, each suited to different disease targets and resource settings. Regionally, endemic zones in sub-Saharan Africa, South and Southeast Asia, and Latin America represent the core addressable market in terms of disease burden, while North America and Europe serve as major procurement, regulatory, and technology development hubs. North America's infectious disease diagnostics segment alone was valued at approximately $889.5 million in 2025, illustrating that high-income regions also contribute substantially through funding, R&D, and regulatory pathways that shape global product availability.

• •Technology categories: rapid lateral flow tests, immunoassays, molecular diagnostics, microscopy/culture
• •Core demand concentrated in sub-Saharan Africa, South/Southeast Asia, and Latin America
• •North America and Europe dominate R&D, funding allocation, and regulatory approval activity
• •North America infectious disease diagnostics: ~$889.5M (2025) projected to ~$1,435.9M (2030)

Who are the notable companies in the industry?

The competitive structure of the NTD diagnosis market is moderately fragmented, combining large diversified manufacturers with mid-sized and specialty players focused on tropical and infectious disease testing. Abbott Laboratories and Thermo Fisher Scientific Inc. lead through broad infectious disease and clinical chemistry portfolios, leveraging established global distribution networks and mature regulatory pathways. F. Hoffmann-La Roche Ltd reinforces this tier with an emphasis on high-throughput molecular and immunoassay platforms serving reference and hospital laboratories. Bio-Rad Laboratories occupies a complementary position with its focus on quality control materials and advanced assay development. Mid-tier innovators, including ZeptoMetrix and InBios International, Inc., differentiate through targeted rapid and lateral flow test formats engineered for field-deployable use in resource-limited settings. Capacity remains concentrated in North America, Western Europe, and select Asian manufacturing hubs, though local production capabilities are gradually emerging in endemic regions through technology-transfer agreements and public-sector collaborations.

• •Moderately fragmented: diversified diagnostic conglomerates alongside mid-sized tropical disease specialists
• •Dual-track competitive model: integrated full-portfolio producers vs. focused rapid-test specialists
• •Core technology routes: lateral flow immunoassay platforms, LAMP-based molecular formats, conventional ELISA and microscopy
• •Manufacturing and R&D capacity concentrated in North America and Europe, with growing in-region production capacity in Asia and Latin America

What are the recent trends and outlook?

The market outlook through 2030 and beyond remains positive, supported by the convergence of increasing NTD program budgets, expanding adoption of rapid and near-patient diagnostics, and growing private-sector investment in neglected disease platforms. Regulatory harmonization efforts and the pursuit of WHO prequalification status are lowering barriers for diagnostic manufacturers seeking entry into large-volume public-health tenders. Emerging digital health integration, such as connected lateral flow readers and mobile-based result reporting, is expected to further strengthen the value proposition of next-generation NTD diagnostics, particularly as climate change and population movement broaden the geographic reach of many NTDs beyond traditional endemic zones.

• •Steady compound growth expected to reach ~$9.6B by 2030; long-range forecasts extend to $13.0-15.1B by 2035
• •WHO prequalification and regulatory streamlining will expand product eligibility for large public-health procurement programs
• •Digital connectivity and mobile result-reporting tools are enhancing the utility and data value of rapid NTD tests
• •Climate-driven range expansion of vector-borne NTDs is likely to broaden the addressable market into previously unaffected regions